Why the BoxX-NoAF trial update matters for AtriCure stock

AtriCure (ATRC) has drawn fresh attention after announcing that its pivotal BoxX-NoAF clinical trial will complete patient enrollment 12 months earlier than planned, raising questions about what earlier data could mean for the stock.

The BoxX-NoAF update has arrived at a time when AtriCure’s share price has fallen 31.46% year to date and its 1 year total shareholder return is down 21.26%, pointing to pressure rather than momentum despite a modest recent rebound.

If this trial news has you thinking more broadly about healthcare-related opportunities, it could be a good moment to scan the market for other potential ideas using our screener for 39 healthcare AI stocks

So with AtriCure’s share price under pressure, a reported intrinsic value that screens higher than today’s US$26.92 level, and an accelerated trial timeline, are you looking at a mispriced stock or a market already factoring in future growth?

Most Popular Narrative: 49% Undervalued

The most followed narrative on AtriCure currently points to a fair value of about $52.78 per share against a last close of $26.92, putting a spotlight on what assumptions could justify that gap.

The successful completion of enrollment in the LeAAPS clinical trial, as well as early activation of the BoxX-NoAF study, are set to substantially increase AtriCure's total addressable market if positive outcomes lead to expanded indications for stroke prevention and preventative cardiac surgery in underserved populations, which will support future revenue and earnings growth.

Curious what sits underneath that near doubling of fair value versus today’s price? The narrative leans heavily on brisk revenue expansion, a swing into profitability and a rich future earnings multiple that is usually reserved for high growth leaders. The real question is how those ingredients fit together in the model.

Result: Fair Value of $52.78 (UNDERVALUED)

However, the story can change quickly if pulsed field ablation rivals keep chipping away at AtriCure’s ablation franchise or if key trials fail to deliver supportive data.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another Angle on Valuation

The analyst driven fair value of about $52.78 per share paints AtriCure as undervalued, but the SWS DCF model points a very different way, with an estimated future cash flow value of just $1.69 per share and a stock price of $26.92 that sits far above that. Which lens do you trust more when cash generation is still limited?

For a closer look at how those cash flow assumptions are built and why they lead to such a low figure compared with the narrative fair value, it is worth walking through the SWS DCF model step by step, starting with the Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out AtriCure for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment split between upside potential and clear concerns, it makes sense to move quickly and review the underlying data yourself, then weigh up the 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you stop with just one stock, you may miss opportunities that fit your style even better, so broaden your search before making any big decisions.

• Spot potential high-upside moves by scanning the market for 23 elite penny stocks with strong financials that already show stronger financial foundations than many expect.
• Target companies that combine quality fundamentals with prices that screen below their estimated worth using the 47 high quality undervalued stocks.
• Prioritize stability and capital strength by reviewing stocks in the solid balance sheet and fundamentals stocks screener (46 results), where balance sheets and core metrics do more of the heavy lifting for you.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.